JF
DNA icon

Jump Financial’s Ginkgo Bioworks DNA Stock Holding History

Jump Financial’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,300
Closed -$252K – 2020
2025
Q3 		$252K Sell
17,300
-352,738
-95% -$4.22M ﹤0.01% 1570
2025
Q2 		$4.16M Buy
+370,038
New +$2.87M 0.05% 476
2025
Q1 		– Sell
-51,415
Closed -$505K – 1681
2024
Q4 		$505K Buy
+51,415
New +$441K 0.01% 1070
2024
Q2 		– Sell
-7,830
Closed -$363K – 1904
2024
Q1 		$363K Buy
7,830
+7,310
+1,406% +$378K 0.01% 1350
2023
Q4 		$35.2K Sell
520
-1,980
-79% -$121K ﹤0.01% 1717
2023
Q3 		$181K Buy
2,500
+1,506
+152% +$120K 0.01% 1557
2023
Q2 		$73.9K Sell
994
-3,690
-79% -$218K ﹤0.01% 1692
2023
Q1 		$249K Buy
+4,684
New +$297K 0.01% 1207
2022
Q4 		– Sell
-267
Closed -$33K – 1668
2022
Q3 		$33K Sell
267
-491
-65% -$58.5K ﹤0.01% 1509
2022
Q2 		$72K Buy
+758
New +$92.5K ﹤0.01% 1475

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jump Financial's DNA Position: Q4 2025 in Review

Jump Financial sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 17,300 shares — an estimated $252K sold.

Jump Financial first reported a position in DNA in Q2 2022 and held it in 10 quarters. The position peaked at $4.16M in Q2 2025. 181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • Jump Financial reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
  • Jump Financial sold 17,300 Ginkgo Bioworks shares in Q4 2025, an estimated $252K.
  • Jump Financial first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 10 quarters.
  • Jump Financial's Ginkgo Bioworks position peaked at $4.16M in Q2 2025.
  • 181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Jump Financial's 13F filing for Q4 2025, filed 17 Feb 2026.